The New England journal of medicine
-
Comment Letter
Sitagliptin and Cardiovascular Outcomes in Type 2 Diabetes.
-
Comment Letter
Electrolyte and Acid-Base Disturbances in Diabetes Mellitus.
-
Randomized Controlled Trial Comparative Study
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trial to compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. ⋯ Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables. (Funded by Pharmacyclics and others; RESONATE-2 ClinicalTrials.gov number, NCT01722487.).